Hims & Hers to offer at-home blood draws, lean into 'peptide innovations' with new acquisitions
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
Why Hims & Hers Stock Dropped Today
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Hims & Hers Health (HIMS) Upward Trajectory Boosted by Recent Acquisition
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
SchaeffersResearch.com16h
Hims and Hers Stock Drops Weight as Earnings Loom
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Hims & Hers Health (HIMS) Projected to Post Quarterly Earnings on Monday
Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...
Hims & Hers acquires U.S.-based peptide facility in California
Hims & Hers announced it has acquired a U.S.-based peptide facility based in California. The company said the acquisition will enable the ...
Hims & Hers: A Glorious Opportunity To Trim (Rating Downgrade)
Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...
Hims & Hers to introduce at-home lab testing with Trybe Labs acquisition
Hims & Hers, a health and wellness platform, is set to introduce at-home lab testing capabilities through the acquisition of ...